12:00 AM
Dec 05, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Gilenya fingolimod regulatory update

The U.K.'s NICE issued a second preliminary appraisal recommending against Gilenya fingolimod to treat relapsing-remitting multiple sclerosis (RRMS), despite a discount proposed by Novartis after a negative appraisal in August. NICE said that with the undisclosed discount, the most plausible incremental cost-effectiveness ratio (ICER) for Gilenya is at least £40,000 ($62,100) per...

Read the full 238 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >